Updates of Radioiodine Treatment for Graves' Disease
International Journal of Thyroidology
;
: 85-90, 2019.
Artigo
em Coreano
| WPRIM
| ID: wpr-785844
ABSTRACT
Radioiodine (RAI) has been used for the treatment of hyperthyroidism and is usually administered orally as sodium iodide (I-131) in solution or a capsule. However, this results in RAI being rapidly incorporated into the thyroid cells, and extensive local tissue damage occurring via beta emissions of I-131. The incidence rate of hypothyroidism is 5–50% at the first year after RAI therapy and is positively associated with the dosage of RAI. RAI has been used since 1960 in Korea; however, there have been few well-designed prospective trials, leaving many questions about indications, optimal dose, efficacy, and side-effects. This review summarizes the latest research pertaining to clinical questions about indications, optimal dose, efficacy, and side-effects.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Iodeto de Sódio
/
Glândula Tireoide
/
Doença de Graves
/
Incidência
/
Estudos Prospectivos
/
Hipertireoidismo
/
Hipotireoidismo
/
Coreia (Geográfico)
Tipo de estudo:
Estudo de incidência
/
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
País/Região como assunto:
Ásia
Idioma:
Coreano
Revista:
International Journal of Thyroidology
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS